Marı́a Teresa Valenzuela
Dados Biográficos
| ID | 10243096 |
|---|---|
| NOME | Marı́a Teresa Valenzuela |
| PRENOMES | Marı́a Teresa |
| SOBRENOME | Valenzuela |
| ASSINATURA | VALENZUELA M T |
| AFILIAÇÕES | Universidad de Los Andes, Chile |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2018 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2023 |
| ÍNDICE H | 0 |
Humoral immunity against Sars-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
Introduction: Severe acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme. The final target is 18 million individuals. The most common vaccines used in Chile are CoronaVac (Sinovac) and BNT162b2 (Pfizer-Biotech). Given the …
Efecto de la vacuna antineumocócica conjugada 10-valente en el área sur de Santiago de Chile, 2009-2015
The introduction of the PCV-10 vaccine into the National Immunization Program has had a positive effect, with a significant reduction in IPD and CAP and in days of hospitalization due to IPD, while preventing cases and deaths
Sem obras proeminentes nesta página.
Efecto de la vacuna antineumocócica conjugada 10-valente en el área sur de Santiago de Chile, 2009-2015
The introduction of the PCV-10 vaccine into the National Immunization Program has had a positive effect, with a significant reduction in IPD and CAP and in days of hospitalization due to IPD, while preventing cases and deaths
Humoral immunity against Sars-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
Introduction: Severe acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme. The final target is 18 million individuals. The most common vaccines used in Chile are CoronaVac (Sinovac) and BNT162b2 (Pfizer-Biotech). Given the …
Antibody (1 obras) · Antibody response (1 obras) · Art (1 obras) · COVID-19 Clinical Research Studies (1 obras) · Humanities (1 obras) · Immune system (1 obras) · Immunology (1 obras) · Internal Medicine (1 obras) · Medicine (1 obras) · Pneumocystis jirovecii pneumonia detection and treatment (1 obras)